Last $12.78 USD
Change Today -0.20 / -1.54%
Volume 87.4K
GNMK On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

genmark diagnostics inc (GNMK) Snapshot

Open
$12.95
Previous Close
$12.98
Day High
$12.95
Day Low
$12.55
52 Week High
01/5/15 - $14.40
52 Week Low
05/21/14 - $8.48
Market Cap
535.3M
Average Volume 10 Days
112.1K
EPS TTM
$-0.92
Shares Outstanding
41.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMARK DIAGNOSTICS INC (GNMK)

Related News

No related news articles were found.

genmark diagnostics inc (GNMK) Related Businessweek News

No Related Businessweek News Found

genmark diagnostics inc (GNMK) Details

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual’s ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual’s increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company’s diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company is engaged in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.

195 Employees
Last Reported Date: 02/24/15

genmark diagnostics inc (GNMK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Senior Vice President of North American Comme...
Total Annual Compensation: $226.2K
Senior Vice President of International
Total Annual Compensation: $154.8K
Senior Vice President of Human Resources
Total Annual Compensation: $248.1K
Compensation as of Fiscal Year 2013.

genmark diagnostics inc (GNMK) Key Developments

GenMark Diagnostics, Inc. Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended Dec. 31, 2014; Provides Earnings Guidance for the Full Year 2015

GenMark Diagnostics, Inc. announced unaudited consolidated earnings results for fourth quarter and full year ended Dec. 31, 2014. For the quarter, the company reported total revenue of $9,826,000, loss from operations of $8,657,000, loss before income taxes of $8,594,000, net loss of $8,612,000 or $0.21 basic and diluted per share, compared to the total revenue of $6,452,000, loss from operations of $10,271,000, loss before income taxes of $10,618,000, net loss of $10,632,000 or $0.26 basic and diluted per share, for the same quarter a year ago. For the year, the company reported total revenue of $30,594,000, loss from operations of $39,054,000, loss before income taxes of $38,836,000, net loss of $38,263,000 or $0.93 basic and diluted per share, net cash used in operating activities of $29,572,000, purchases of property and equipment of $5,726,000 compared to the total revenue of $27,404,000, loss from operations of $34,880,000, loss before income taxes of $33,599,000, net loss of $33,643,000 or $0.95 basic and diluted per share, net cash used in operating activities of $23,796,000, purchases of property and equipment of $4,270,000 for the previous year. The company announced earnings guidance for the full year 2015. For full year 2015, the company expects revenue in the range of $38 to $40 million and Gross Margin in the range of 53-55%.

GenMark Diagnostics, Inc. Announces Board Changes

GenMark Diagnostics, Inc. announced the appointment of Lisa Giles, President and CEO of Giles & Associates Consultancy, and Michael Kagnoff, a partner at DLA Piper (US), to its board of directors. At the same time Steve Worland has resigned from the Board. Ms. Giles has been the President and CEO of Giles & Associates Consultancy since 2000, and CEO of Optivara, Inc. since 2013. Mr. Kagnoff has served as a partner at DLA Piper (US) since April 2008. Prior to joining DLA Piper, he was a stockholder at Heller Ehrman LLP. He has provided legal and business advice on a range of topics, including strategic transactions, corporate governance, and compensation matters. The appointments of Ms. Giles and Mr. Kagnoff were effective February 19, 2015. Each was appointed as a Class III director, with a term of office expiring at the company’s 2016 annual meeting of shareholders. With their addition to the Board, Giles will become a member of the Audit Committee and Kagnoff will become a member of the Corporate Governance and Nominating Committee.

GenMark Diagnostics, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 02:50 PM

GenMark Diagnostics, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 02:50 PM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States. Speakers: Hany Massarany, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNMK:US $12.78 USD -0.20

GNMK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $56.76 USD -0.52
Luminex Corp $15.64 USD -0.45
Nanosphere Inc $0.36 USD -0.0285
QIAGEN NV €22.17 EUR -0.038
Sequenom Inc $3.69 USD +0.15
View Industry Companies
 

Industry Analysis

GNMK

Industry Average

Valuation GNMK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMARK DIAGNOSTICS INC, please visit www.genmarkdx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.